Literature DB >> 5159129

Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).

M D Yahr, R C Duvoisin, M R Mendoza, M J Schear, R E Barrett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5159129

Source DB:  PubMed          Journal:  Trans Am Neurol Assoc        ISSN： 0065-9479


× No keyword cloud information.
  5 in total

Review 1.  Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 2.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 3.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

4.  Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.

Authors:  C D Marsden; P E Barry; J D Parkes; K J Zilkha
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-02       Impact factor: 10.154

5.  [The "off-on" phenomenon during treatment of parkinson's disease with levodopa (author's transl)].

Authors:  J Wajsbort
Journal:  J Neurol       Date:  1977-04-28       Impact factor: 4.849
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.